Organization
Seoul National University Hospital, Cancer Research Institute, Seoul, South Korea
1 abstract
Abstract
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Seoul National University Hospital, Cancer Research Institute, Seoul, South Korea, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,